BIIB240920P235000
- 35.79
- 0.000.00%
Biogen Newsroom
Here's Why Biogen Inc. (BIIB) Is a Strong Value Stock
Cautious Optimism Amidst Growth Deceleration and Rising Competition for Biogen
US Rheumatologists Believe Biogen's Litifilimab Is the Leading SLE Pipeline Asset Poised to Offer Improvement Over Benlysta and Saphnelo Based on Clinical Trial Data
Jones Research Starts Larimar at Buy, Cites Lead Asset Nomlabofusp
Healthcare Stocks Have Popped. Consider These 2 That Haven't. -- Barrons.com
Biogen Names Lloyd Minor, Menelas Pangalos to Board >BIIB
Express News | Biogen Board Appoints Two New Independent Directors
Press Release: Biogen Board Appoints Two New Independent Directors
Bio-Thera Solutions, Biogen Publish Phase 3 Clinical Trial Data for TOFIDENCE, An Approved Biosimilar Referencing Tocilizumab In Arthritis Research & Therapy
Express News | Bio-Thera Solutions: Comparable Clinical Efficacy, Safety in Treatment Period 2 Is Maintained After Switch From Reference Tocilizumab to Tofidence
Express News | Bio-Thera Solutions and Biogen Publish Phase 3 Clinical Trial Data for Tofidence™
C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen
Bernie Sanders Says If You're Poor In America You'll Live 10-15 Years Less: 'Anybody Else See A Problem With That?'
Express News | Cantor Fitzgerald Reiterates Overweight on Biogen, Maintains $292 Price Target
Biogen Analyst Ratings
Biogen/Eisai's Leqembi Brings Hope To Early Alzheimer's Patients Amid Logistical Challenges
50 Stocks That May See Selling Pressure as Investors Begin Looking to Book Tax Losses
Biogen's Higher Spinraza Dose Shows Better Efficacy in Phase II/III Trial
Pandemic Darling Moderna Needs a Reality Check -- Heard on the Street -- WSJ
Biogen Inc. (NASDAQ:BIIB) Not Lagging Market On Growth Or Pricing